Pfizer Inc. $PFE Shares Acquired by United Asset Strategies Inc.

United Asset Strategies Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 762.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 231,199 shares of the biopharmaceutical company’s stock after acquiring an additional 204,406 shares during the quarter. United Asset Strategies Inc.’s holdings in Pfizer were worth $6,594,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Choreo LLC lifted its holdings in Pfizer by 6.7% in the 3rd quarter. Choreo LLC now owns 188,518 shares of the biopharmaceutical company’s stock worth $5,376,000 after buying an additional 11,810 shares during the period. Livelsberger Financial Advisory bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $137,000. Values Added Financial LLC purchased a new position in shares of Pfizer during the third quarter valued at approximately $210,000. Dynamic Financial Group increased its stake in shares of Pfizer by 1.5% during the third quarter. Dynamic Financial Group now owns 69,069 shares of the biopharmaceutical company’s stock valued at $1,970,000 after buying an additional 1,014 shares during the period. Finally, TOWER TRUST & INVESTMENT Co increased its stake in shares of Pfizer by 1.9% during the third quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock valued at $551,000 after buying an additional 357 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 1.6%

PFE stock opened at $29.91 on Friday. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $30.44. The company has a market capitalization of $170.49 billion, a price-to-earnings ratio of 9.66, a price-to-earnings-growth ratio of 2.00 and a beta of 0.32. The business’s 50 day moving average price is $28.49 and its two-hundred day moving average price is $26.76. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that ELREXFIO met the primary endpoint in a second Phase 3 multiple myeloma trial. The result strengthens the drug’s position as a potential growth product that could help offset declines in pandemic-related revenue. Pfizer’s Elrexfio meets primary endpoint in second Phase III myeloma trial
• Positive Sentiment: Pfizer entered an agreement with Edison Scientific to accelerate research and development. While financial terms and specific programs were not disclosed, the collaboration could improve drug-discovery productivity and support the company’s longer-term pipeline. Edison Scientific Announces Agreement with Pfizer
• Positive Sentiment: A new industry report projects the global HER2-targeted therapies market will grow at roughly 8% annually through 2026. Pfizer is listed among companies advancing antibody-drug conjugates and precision-oncology treatments, providing a favorable backdrop for its oncology strategy. Global HER2 Targeted Therapies Market Report 2026
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter results, scheduled for November 3. Analysts are assessing whether non-COVID products, cost controls and progress in obesity treatments can counter continued erosion in COVID-product sales. Obesity Pipeline vs. COVID Drag
• Negative Sentiment: ELREXFIO’s trial success came with higher infection rates, creating a safety consideration that could affect adoption, labeling or investor expectations despite the efficacy milestone. Pfizer’s ELREXFIO Meets Phase 3 Endpoint

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. JPMorgan Chase & Co. boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Finally, Scotiabank raised their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 6th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.72.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.